SlideShare a Scribd company logo
1 of 5
Download to read offline
Pharmacovigilance
                 2010
               "Overseeing risks & Optimizing drug safety in today’s pharma market”


                         January 21st - 22nd 2010, (Venue TBC), Mumbai, India



 Key Speakers:

Veena Rajan, Head - Patient Safety, AstraZeneca

Viraj Rajadhyaksha, Senior Manager, Operations, Planning & Management Clinical Research, Pfizer

Simrat Sohal, Head - Pharmacovigilance, Eli Lilly

Bhaswat S. Chakraborty, Senior VP, R&D, Cadila Pharmaceuticals

Prashanth BSB, Medical & Safety expert (Regulatory Affairs), Cipla

Deven Parmar MD, Vice President - Clinical Research & Pharmacovigilance, Wockhardt

Milind Antani, Head-Pharma LifeSciences group, Nishith Desai Associates

Arani Chatterjee, Vice President, Clinical Research, Panacea Biotec

Arunima Sen, Manager Medical Team, MMS Holdings Incorporation

Krathish Bopanna, Senior Vice President, Acunova

D.D.Gupta, Vice President, Indian Pharmacological Society

Gopal Pande, Scientist, Center for Cellular & Molecular Biology




Media Partners



                                                                                                  Organised By
Pharmacovigilance 2010

                 January 21st, 22nd 2010, Hotel (TBC), Mumbai, India.

Conference Intro:

Pharmacovigilance is the science and actions relating to discovery, evaluation, understanding and prevention of adverse effects or any other likely medicine
related problems. The main aim of pharmacovigilance is to improve patient care and safety in relation to the use of medicines and other interventions. Despite
all the benefits of medicines in disease management, there continues to be problems related to adverse reactions which are important cause for morbidity and
morality in many countries. Significant harm to even a few patients not only destroys the credibility of the medicine, the patients also tend to loose trust on
health system. A good Pharmacovigilance system will identify the risks in the shortest possible time, so that any harm can be avoided or minimized. The most
frightening thought for any pharma company is the prospect of a drug withdrawal. As the costs associated with product withdrawals escalate, the importance of
pharmacovigilance increases.

Pharmacovigilance 2010 conference will discuss the on-going pressing concerns faced in drug safety, addressing the risks, timeline and budget constraints,
whilst effectively tackling key challenges in overcoming trials agreement and site contract negotiation hurdles. This conference brings together top
pharmaceutical, biotechnology and regulatory representatives in a forum that addresses the key issues of the industry. The in-depth program covers discussion
on the detection, analysis and prevention of adverse drug reactions with case studies and industry experiences. Understand and learn the latest insights, tools
and knowledge to ensure that you and your firm catch up with the current and future market. Analyze along with the market leaders, the latest developments
in pharmacovigiance which would shape your organization-wide risk management strategy.




                                Reasons to Register:
Reviewing the best revenue generating models suitable for current and future PV market.
·                                                                                                                            Who Should Attend:
Grabbing the opportunity: learning about the challenges & complexities in the role
·
· practices, service offerings & deployment
Best                                                                                                        VP's, Directors, CRO's, Heads and Managers of:
Global marketing strategies in order to engage with regulatory centres of excellence on
·
 pharmacovigilance and to understand their perspectives on best practice & future trends                    Pharmacovigilance Strategy
                                                                                                            ?
Improving patient care and safety in relation to use of medicines and all
·                                                                                                           ?Safety/Risk Management
                                                                                                            Drug
 medical and paramedical interventions                                                                      Information and Clinical Data Management
                                                                                                            ?
Exploiting the role of electronic data standards and controlled vocabularies in pharmacovigilance
·                                                                                                           ? Research & Development
                                                                                                            Clinical
Positioning yourself in light of new market entries
·                                                                                                           Product Safety/Assurance Assessment
                                                                                                            ?
Analyzing the worldwide trends in PV & lessons for India.
·                                                                                                           ? Safety, Outcomes Research & Data Analysis
                                                                                                            Patient
Discover approaches for collecting, integrating and analyzing all of the safety data generated
·                                                                                                           Epidemiology project management
                                                                                                            ?
 from preclinical models                                                                                    Regulatory Affairs and Compliance
                                                                                                            ?
Updating yourself with legislations, policies, systems, technology,
·                                                                                                           ? & Marketing
                                                                                                            Sales
 communication strategies and best practice in PV                                                           ? manufacturers
                                                                                                            Biotech
Dwell ahead of regulatory developments & improving your risk management strategies in a cost
·
 effective way




                            Target Audience:
                                                                                                        Why should you attend:
  Pharmaceutical and Biotechnological Companies
  ?
  Contract Research Organisations (CROs),
  ?                                                                               Pharmacovigilance 2010 - "Overseeing risks & Optimizing drug safety in
  Contract Manufacturing Organisations (CMOs),
  ?                                                                               today's pharma market”
  ?Regulators,
  Drug                                                                            Get more from the event, with a broader scope bringing the whole
  Intellectual Property/Law Firms,
  ?                                                                               communications value chain together. Enjoy and make the best out of
  Academia,
  ?                                                                               our dedicated networking drinks time, meet the leading international
  Government Bodies, Regulatory Affairs, Clinical Research Scientists
  ?                                                                               vendors showcasing the products of tomorrow in the co-located
  Pharmaceutical manufacturing and distributing companies
  ?                                                                               exhibition. Expand your knowledge of the latest business models and
  Wholesalers
  ?                                                                               strategies in the high-level conference.
  Pharmaceutical packaging and labelling companies
  ?
  ? suppliers
  Service
  Pharmaceutical specialist couriers
  ?
  ? health and regulatory bodies,
  Public
  Anti-counterfeiting organisations
  ?
  Non-governmental healthcare organisations
  ?
                                                                                                        Delegate Registration:
  ? Recruitment Companies
  Patient
  Non-profit Organisations/Association, Consultants
  ?                                                                               To register and to book your seats at the conference - please email your
                                                                                  interest to delegate@virtueinsight.com



            Sponsorship & Exhibition Opportunities:

   If you would like to benefit by promoting your organization at one of
                                                                                                           About Virtue Insight:
   our events then exhibit is perfect for you.
                                                                                   Virtue Insight equips business professionals around the world with the latest indepth
   ·   Hosting a networking drinks reception                                       industry knowledge and provides networking opportunities in the telecom and
   ·   Increase and maintain brand awareness                                       pharmaceutical industry. Our aim is to provide a platform to share knowledge and
   ·   Taking an exhibition space at the conference                                insights and provide our event attendees to network effectively and deliver maximum
   ·   Target your marketing campaign                                              ROI by make new business alliances. We strive to produce high quality conferences
                                                                                   which include the latest topics which are delivered by world class leaders of the
   ·   Advertising in the delegate documentation pack                              industry.
   ·   Providing branded bags, pens, gifts, etc.
   ·   Network with industry decision-makers                                       Our motto is to offer our customers the expertise and connections for a profitable
   ·   Meet potential clients & Present your products and ideas                    business. Our events encompass an optimum chance to gain maximum value in terms
                                                                                   of networking and an opportunity to sponsor and exhibit to attract new business
   Any questions on Sponsorships or Exhibition – Email your queries to             alliances.
   sarika.sareen@virtueinsight.com
Pharmacovigilance 2010

                                                    Day One, 21st January 2010

08:45 - Coffee and registration - An opportunity to meet and to
         network with your conference colleagues.                          14:40 – Growth of pharmacovigilance systems - India

09:30 - Chair's opening remarks                                            ? of developing PV in India
                                                                           Benefits

Arani Chatterjee, Vice President, Clinical Research Panacea Biotec         ?
                                                                           Analyzing the current and the future of PV in India

09:40 - Observe the current & future market of Pharmacovigilance           Demand for efficient PV by middle class Indians
                                                                           ?


Analysing the current market situation and revealing the key revenue
?                                                                          Deven Parmar MD, Vice President                 -   Clinical    Research      &
   drivers for the future markets.                                         Pharmacovigilance, Wockhardt

? are the steps to be taken if the industry is to achieve full
What                                                                       15:20 – Afternoon tea
   potential?

Challenges and Opportunities in 21st Century Safety Testing
?                                                                          15:40 – Panel Discussion - Regulator's perspective

Determine the key considerations in implementing a progressive
?                                                                          ?
                                                                           Pharmacovigilance from the Regulator's Perspective – Latest Updates
   pharmacovigilance strategy
                                                                           ?
                                                                           Understanding how companies can work more successfully with regulators
10:20 - Next generation pharmacovigilance - opportunities and
finding solutions to the challenges of drug safety                         ?
                                                                           What can the regulators do to help industry?

?
Highlighting the critical new importance of pharmacovigilance and risk     ?
                                                                           Determining the best strategy to secure approval.
management for successful drug development
                                                                           ?
                                                                           An overview of the Global Regulatory Safety Information Database
?
New opportunities for high performance in pharmacovigilance

?
Elaborating the new globalization of pharmacovigilance standards           Moderator:

11:00 – Morning coffee & Discussion                                        Milind Antani,    Head-Pharma       LifeSciences    group,     Nishith   Desai
                                                                           Associates
11:20 – Pre-Approval periodic safety reporting using DSUR & post
marketing reporting using PSUR - Understanding the essentials              Panellists:

Sanish Davis, Clinical research manager, PGRD, Pfizer                      16:20 – Emerging technologies and strategies for drug safety
                                                                           evaluation
12:00– Panel discussion: Challenges in upcoming markets
                                                                           ? key technologies for predicting drug safety in the earliest stages of
                                                                           Assess
?
Successful strategies to face the future challenges in pharmacovigilance   discovery and clinical development

?
Analyzing the changing business environment                                ?
                                                                           Analyzing the role of public-private consortia in solving key issues within
                                                                           the field of predictive safety.
?
Evaluating where are the opportunities and threats in emerging
 markets                                                                   ? predictive safety technologies can provide potential cost savings
                                                                           Which
                                                                           and improvements in attrition rates and assess the challenges and risks
Moderator:                                                                 associated with the implementation.

Gopal Pande, Scientist, Center for Cellular & Molecular Biology            ?
                                                                           Understand the latest strategies to improve safety evaluation in early
                                                                           clinical development
Panellists:

Arunima Sen, Manager Medical Team, MMS Holdings Incorporation              17:00 – Chairperson's closing remarks and End of Conference

Veena Rajan, Head - Patient Safety, AstraZeneca

12:40 – Networking luncheon

14:00 - Role of Therapeutic alliance in PV                                   17:20 - Networking Drinks - Take your discussions
                                                                               further & build new relationships in a relaxed
D.D.Gupta, Vice President, Indian Pharmacological Society                                   & informal setting...
Pharmacovigilance 2010

                                                    Day Two, 22nd January 2010


08:45 – Coffee and registration – An opportunity to meet and to      14:00 – Pharmacovigilance quality assurance
network with your conference colleagues.
                                                                     ·Pharmacovigilance QA as a Corporate competitive advantage

09:30 – Chair's opening remarks                                      ·Pharmacovigilance QA Surveillace Programme

TBC                                                                  ·Application of Quality Risk Management principles for ensuring an
                                                                      effective PV audit programme

09:40 – Data mining & signal detection in Pharmacovigilance          ·Creation of PV Quality Indicators for monitoring status of quality and
                                                                      future auditing needs
Bhaswat S. Chakraborty, Senio VP, R&D, Cadila Pharmaceuticals
                                                                     ·Electronic-submissions and the associated quality issues
10:20 – Pharmacovigilance in focus

·Economic impact of ADR                                              14:40 – Risk management -

·Thalidomide status through PV                                       ·Lessons to be learned from extensive drug safety research

·Real lessons from Vioxx                                             ·Cutting-edge risk management, how to prepare for the
                                                                      wWorst
·Best-selling drugs & adv through PV for these drugs
                                                                     ·Managing developments and adapting to changing
·Practical problems & Challenges in PV                                information

·Penalties on non-complaiance to PV                                  ·Constant improvement in risk management strategies

Prashanth BSB, Medical & Safety expert (Regulatory Affairs), Cipla   ·Developing and maintaining exemplary drug safety standards

11:00 – Morning coffee & Discussion
                                                                     15:20 – Afternoon tea

11:20 – Panel Discussion - Working towards patient subject safety
from early development                                               15:40 – Challenges in Pharmacovigilance: Different Sponsors, Same
                                                                     Drug
·Advanced Pharmacology Techniques and Methodologies to Improve
 Safety                                                              ?are current “best practices” in this challenging area?
                                                                     What

·Putting the patient first – The importance of developing a          ? “continuous safety monitoring” be achieved?
                                                                     How can
 comprehensive post-marketing surveillance strategy
                                                                     ·What are issues in signal detection across sponsors and trans-nationally?

Moderator:                                                           ·Best methods for pharmacovigilance, signal detection, risk management in
                                                                       this setting
Panellists:

Atul Jain, Vice-principal & Professor & Head of Pharmacology         16:20 – Panel Discussion – SWOT analysis
Deptt., T.M.U.Medical College

                                                                     Strength, Weakness, Opportunities & Threats of Pharmacovigilance in India
12:00 – Challenges in the local regulations for pharmcovigilnce      (Overall review of this Pharmacovigilance 2010 conference)

Simrat Sohal, Head - Pharmacovigilance, Eli Lilly
                                                                     Moderator:

12:40 – Networking luncheon
                                                                     Panellists:

                                                                     Krathish Bopanna, Senior Vice President, Acunova

                                                                     Viraj Rajadhyaksha, Senior Manager, Operations,               Planning       &
                                                                     Management Clinical Research, Pfizer, India


                                                                     17:00 – Chairperson's closing remarks and End of Conference
Registration Form
                                                                        Pharmacovigilance 2010
                                                                        21st - 22nd January, 2010


For Multiple Bookings
Photocopy this form...
                                                                                                      Queries:
Special Price INR (Please Tick)                                                                       Should you have any questions on bookings,
                                                                                                      Please feel free to contact us.
2 Day conference                            Fee: INR 12,000 + Tax
1 Day conference                            Fee: INR 7,000 + Tax                                      Email: delegate@virtueinsight.com
                                                                                                      Web: http://www.virtueinsight.com
Academic Price (Students)                                                                             India Office: Tel: +0091 44 64998743

2 Day conference                            Fee: INR 5,000 + Tax
1 Day conference                            Fee: INR 3,000 + Tax                                      Payment terms:
                                                                                                      Virtue Insight requires the full amount to be paid before the
Registration Form Details:                                                                            conference. Virtue Insight may refuse entry to delegates who have
                                                                                                      not paid their invoice in full.
Forename ............................Surname ................................
                                                                                                      Substitutions/name changes or cancellations:
                                                                                                      There is a 50% liability on all bookings once made, whether by post,
Job Title ..............................Company ................................                      fax, or email. There is a no refund policy for cancellations received
                                                                                                      on or after one month before the start of the event. Should you decide
                                                                                                      to cancel after this date, the full invoice must be paid. Conference
Official Contact Number .......................................................                       notes will then be sent to you. Unfortunately, we are unable to transfer
                                                                                                      places between conferences and executive briefings. However, if you
                                                                                                      cannot attend the conference, you may make a substitution/name
Address .............................................................................                 change at any time, as long as we are informed in writing by email,
                                                                                                      fax or post. Name changes and substitutions must be from the same
                                                                                                      company or organization and are not transferable between countries.
           .............................................................................
                                                                                                      Indemnity:
                                                                                                      Virtue Insight reserves the right to make alterations to the
Country ...............................Postcode..................................                     conference/executive briefing content, timing, speakers or venue
                                                                                                      without notice. The event may be postponed or cancelled due to
                                                                                                      unforeseen events beyond the control of Virtue Insight. If such a
Phone ..................................Fax ........................................                  situation arises, we will refund your registration fee and we will try
                                                                                                      to reschedule the event.

Email .................................................................................               Fee:
                                                                                                      The conference fee includes lunch, refreshments and conference papers
                                                                                                      provided on the day. This fee does not include travel or hotel
I confirm that I have read & agree to the                                                             accommodation.
terms and conditions of booking..... (Please Tick)
                                                                                                      How we will contact you:
                                                                                                      Virtue Insight's preferred method of communication is by email and
Signature ...........................................................................                 phone. Please ensure that you complete the registration form in full
                                                                                                      so that we can contact you.

Methods of Payments:

By Cheque - Complete and return the above registration form via
post or email, together with your cheque payable to Virtue Insight.

By Bank Transfer -

Account Name - Virtue Insight                                                                         News Updates:
Account Number - 830092431
Bank Address - Indian Bank.                                                                           Please tick if you do not wish to receive email updates in
118 - 119, Indira Nagar, Valasaravakkam,                                                              the future
Chennai 600 087,Tiruvallur district,Tamil Nadu, India




                                                                                           www.virtueinsight.com

More Related Content

What's hot

Drug Information Agency (dia) 7th annual conference: Kapil Khandelwal, www.ka...
Drug Information Agency (dia) 7th annual conference: Kapil Khandelwal, www.ka...Drug Information Agency (dia) 7th annual conference: Kapil Khandelwal, www.ka...
Drug Information Agency (dia) 7th annual conference: Kapil Khandelwal, www.ka...Kapil Khandelwal (KK)
 
SMi Group's Pre-filled Syringes East Coast 2020
SMi Group's Pre-filled Syringes East Coast 2020 SMi Group's Pre-filled Syringes East Coast 2020
SMi Group's Pre-filled Syringes East Coast 2020 Dale Butler
 
SMi Group's Pre-filled Syringes West Coast 2020 conference
SMi Group's Pre-filled Syringes West Coast 2020 conferenceSMi Group's Pre-filled Syringes West Coast 2020 conference
SMi Group's Pre-filled Syringes West Coast 2020 conferenceDale Butler
 
Product Launch Failure & Success Study
Product Launch Failure & Success StudyProduct Launch Failure & Success Study
Product Launch Failure & Success StudyBest Practices, LLC
 
The Statisticians Role in Pharmaceutical Development
The Statisticians Role in Pharmaceutical DevelopmentThe Statisticians Role in Pharmaceutical Development
The Statisticians Role in Pharmaceutical DevelopmentAshwani Dhingra
 
Creating value beyond the pill
Creating value beyond the pillCreating value beyond the pill
Creating value beyond the pillexecutiveinsight
 
Highly Potent Active Pharmaceutical Ingredients 2017
Highly Potent Active Pharmaceutical Ingredients 2017Highly Potent Active Pharmaceutical Ingredients 2017
Highly Potent Active Pharmaceutical Ingredients 2017Fateja Begum
 
Success Factors and Failure Points in Biopharmaceutical Product Launches: An ...
Success Factors and Failure Points in Biopharmaceutical Product Launches: An ...Success Factors and Failure Points in Biopharmaceutical Product Launches: An ...
Success Factors and Failure Points in Biopharmaceutical Product Launches: An ...Best Practices
 
How Technology Can Help With Sales and Marketing Compliance
How Technology Can Help With Sales and Marketing ComplianceHow Technology Can Help With Sales and Marketing Compliance
How Technology Can Help With Sales and Marketing ComplianceGood Promotional Practices
 
Market Access - Getting ready for Personalized Medicine!
Market Access - Getting ready for Personalized Medicine!Market Access - Getting ready for Personalized Medicine!
Market Access - Getting ready for Personalized Medicine!executiveinsight
 
SMi Group's Adaptive Designs in Clinical Trials conference
SMi Group's Adaptive Designs in Clinical Trials conferenceSMi Group's Adaptive Designs in Clinical Trials conference
SMi Group's Adaptive Designs in Clinical Trials conferenceDale Butler
 
SMi Group's 9th annual Pre-filled Syringes Europe 2017
SMi Group's 9th annual Pre-filled Syringes Europe 2017 SMi Group's 9th annual Pre-filled Syringes Europe 2017
SMi Group's 9th annual Pre-filled Syringes Europe 2017 Dale Butler
 
SMi Group's Drug Discovery 2018
SMi Group's Drug Discovery 2018SMi Group's Drug Discovery 2018
SMi Group's Drug Discovery 2018Dale Butler
 
Success Factors and Failure Points in Metabolic Product Launches
Success Factors and Failure Points in Metabolic Product LaunchesSuccess Factors and Failure Points in Metabolic Product Launches
Success Factors and Failure Points in Metabolic Product LaunchesBest Practices, LLC
 
Pharmaceutical competitive intelligence
Pharmaceutical competitive intelligencePharmaceutical competitive intelligence
Pharmaceutical competitive intelligenceferiel abidi
 
分会场3-01-曾小明-论文-公司级过程安全管理和风险管理:三个关键要素
分会场3-01-曾小明-论文-公司级过程安全管理和风险管理:三个关键要素分会场3-01-曾小明-论文-公司级过程安全管理和风险管理:三个关键要素
分会场3-01-曾小明-论文-公司级过程安全管理和风险管理:三个关键要素XiaoMing Zeng
 

What's hot (20)

Quản lý rủi ro chất lượng trong GMP EU
Quản lý rủi ro chất lượng trong GMP EUQuản lý rủi ro chất lượng trong GMP EU
Quản lý rủi ro chất lượng trong GMP EU
 
Drug Information Agency (dia) 7th annual conference: Kapil Khandelwal, www.ka...
Drug Information Agency (dia) 7th annual conference: Kapil Khandelwal, www.ka...Drug Information Agency (dia) 7th annual conference: Kapil Khandelwal, www.ka...
Drug Information Agency (dia) 7th annual conference: Kapil Khandelwal, www.ka...
 
SMi Group's Pre-filled Syringes East Coast 2020
SMi Group's Pre-filled Syringes East Coast 2020 SMi Group's Pre-filled Syringes East Coast 2020
SMi Group's Pre-filled Syringes East Coast 2020
 
SMi Group's Pre-filled Syringes West Coast 2020 conference
SMi Group's Pre-filled Syringes West Coast 2020 conferenceSMi Group's Pre-filled Syringes West Coast 2020 conference
SMi Group's Pre-filled Syringes West Coast 2020 conference
 
E-Sampling Report Summary
E-Sampling Report SummaryE-Sampling Report Summary
E-Sampling Report Summary
 
E Sampling Summary
E Sampling SummaryE Sampling Summary
E Sampling Summary
 
Product Launch Failure & Success Study
Product Launch Failure & Success StudyProduct Launch Failure & Success Study
Product Launch Failure & Success Study
 
The Statisticians Role in Pharmaceutical Development
The Statisticians Role in Pharmaceutical DevelopmentThe Statisticians Role in Pharmaceutical Development
The Statisticians Role in Pharmaceutical Development
 
Creating value beyond the pill
Creating value beyond the pillCreating value beyond the pill
Creating value beyond the pill
 
Highly Potent Active Pharmaceutical Ingredients 2017
Highly Potent Active Pharmaceutical Ingredients 2017Highly Potent Active Pharmaceutical Ingredients 2017
Highly Potent Active Pharmaceutical Ingredients 2017
 
Success Factors and Failure Points in Biopharmaceutical Product Launches: An ...
Success Factors and Failure Points in Biopharmaceutical Product Launches: An ...Success Factors and Failure Points in Biopharmaceutical Product Launches: An ...
Success Factors and Failure Points in Biopharmaceutical Product Launches: An ...
 
How Technology Can Help With Sales and Marketing Compliance
How Technology Can Help With Sales and Marketing ComplianceHow Technology Can Help With Sales and Marketing Compliance
How Technology Can Help With Sales and Marketing Compliance
 
Intro4
Intro4Intro4
Intro4
 
Market Access - Getting ready for Personalized Medicine!
Market Access - Getting ready for Personalized Medicine!Market Access - Getting ready for Personalized Medicine!
Market Access - Getting ready for Personalized Medicine!
 
SMi Group's Adaptive Designs in Clinical Trials conference
SMi Group's Adaptive Designs in Clinical Trials conferenceSMi Group's Adaptive Designs in Clinical Trials conference
SMi Group's Adaptive Designs in Clinical Trials conference
 
SMi Group's 9th annual Pre-filled Syringes Europe 2017
SMi Group's 9th annual Pre-filled Syringes Europe 2017 SMi Group's 9th annual Pre-filled Syringes Europe 2017
SMi Group's 9th annual Pre-filled Syringes Europe 2017
 
SMi Group's Drug Discovery 2018
SMi Group's Drug Discovery 2018SMi Group's Drug Discovery 2018
SMi Group's Drug Discovery 2018
 
Success Factors and Failure Points in Metabolic Product Launches
Success Factors and Failure Points in Metabolic Product LaunchesSuccess Factors and Failure Points in Metabolic Product Launches
Success Factors and Failure Points in Metabolic Product Launches
 
Pharmaceutical competitive intelligence
Pharmaceutical competitive intelligencePharmaceutical competitive intelligence
Pharmaceutical competitive intelligence
 
分会场3-01-曾小明-论文-公司级过程安全管理和风险管理:三个关键要素
分会场3-01-曾小明-论文-公司级过程安全管理和风险管理:三个关键要素分会场3-01-曾小明-论文-公司级过程安全管理和风险管理:三个关键要素
分会场3-01-曾小明-论文-公司级过程安全管理和风险管理:三个关键要素
 

Similar to Pharmacovigilance 2010

5th Annual Pharmacovigilance (2010) Ts
5th Annual Pharmacovigilance (2010) Ts5th Annual Pharmacovigilance (2010) Ts
5th Annual Pharmacovigilance (2010) Tstatisalla
 
Pharmacovigilance at the Intersection of Healthcare and Life Sciences
Pharmacovigilance at the Intersection of Healthcare and Life SciencesPharmacovigilance at the Intersection of Healthcare and Life Sciences
Pharmacovigilance at the Intersection of Healthcare and Life SciencesPerficient
 
Leveraging Technology in Pharma Marketing - Interview with: Dr. Trenor Willia...
Leveraging Technology in Pharma Marketing - Interview with: Dr. Trenor Willia...Leveraging Technology in Pharma Marketing - Interview with: Dr. Trenor Willia...
Leveraging Technology in Pharma Marketing - Interview with: Dr. Trenor Willia...Marketing Network marcus evans
 
7th Annual Pharmacovigilance (2012) Pp
7th Annual Pharmacovigilance (2012) Pp7th Annual Pharmacovigilance (2012) Pp
7th Annual Pharmacovigilance (2012) PpPiyush Patel
 
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011Nathan White, CPC
 
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Bhaswat Chakraborty
 
9th pharmacovigilance 2015
9th pharmacovigilance 20159th pharmacovigilance 2015
9th pharmacovigilance 2015Wildfrontech
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014Dinesh T
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014Dinesh T
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014Dinesh T
 
Integrated Safety and Risk Management Solutions - Addressing the Needs of Sma...
Integrated Safety and Risk Management Solutions - Addressing the Needs of Sma...Integrated Safety and Risk Management Solutions - Addressing the Needs of Sma...
Integrated Safety and Risk Management Solutions - Addressing the Needs of Sma...Covance
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014Dinesh T
 
6th annual pharmacovigilance conference (2011)
6th annual pharmacovigilance conference (2011)6th annual pharmacovigilance conference (2011)
6th annual pharmacovigilance conference (2011)Pranita Nangia
 
11th Annual Biosimilars Uk (2012)
11th Annual Biosimilars Uk (2012)11th Annual Biosimilars Uk (2012)
11th Annual Biosimilars Uk (2012)shad121
 
Drug Regulatory Affairs
Drug Regulatory AffairsDrug Regulatory Affairs
Drug Regulatory AffairsNamdeo Shinde
 
How is digital innovation affecting the pharmaceutical industry- Presentation
How is digital innovation affecting the pharmaceutical industry- PresentationHow is digital innovation affecting the pharmaceutical industry- Presentation
How is digital innovation affecting the pharmaceutical industry- PresentationGraphi Tales
 
Redefining pharmacovigilance-with-social-media
Redefining pharmacovigilance-with-social-mediaRedefining pharmacovigilance-with-social-media
Redefining pharmacovigilance-with-social-mediaDheeraj Girdhani
 

Similar to Pharmacovigilance 2010 (20)

5th Annual Pharmacovigilance (2010) Ts
5th Annual Pharmacovigilance (2010) Ts5th Annual Pharmacovigilance (2010) Ts
5th Annual Pharmacovigilance (2010) Ts
 
Pharmacovigilance at the Intersection of Healthcare and Life Sciences
Pharmacovigilance at the Intersection of Healthcare and Life SciencesPharmacovigilance at the Intersection of Healthcare and Life Sciences
Pharmacovigilance at the Intersection of Healthcare and Life Sciences
 
Leveraging Technology in Pharma Marketing - Interview with: Dr. Trenor Willia...
Leveraging Technology in Pharma Marketing - Interview with: Dr. Trenor Willia...Leveraging Technology in Pharma Marketing - Interview with: Dr. Trenor Willia...
Leveraging Technology in Pharma Marketing - Interview with: Dr. Trenor Willia...
 
7th Annual Pharmacovigilance (2012) Pp
7th Annual Pharmacovigilance (2012) Pp7th Annual Pharmacovigilance (2012) Pp
7th Annual Pharmacovigilance (2012) Pp
 
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011
 
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
 
9th pharmacovigilance 2015
9th pharmacovigilance 20159th pharmacovigilance 2015
9th pharmacovigilance 2015
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014
 
Integrated Safety and Risk Management Solutions - Addressing the Needs of Sma...
Integrated Safety and Risk Management Solutions - Addressing the Needs of Sma...Integrated Safety and Risk Management Solutions - Addressing the Needs of Sma...
Integrated Safety and Risk Management Solutions - Addressing the Needs of Sma...
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014
 
9th pharmacovigilance 2015
9th pharmacovigilance 20159th pharmacovigilance 2015
9th pharmacovigilance 2015
 
6th annual pharmacovigilance conference (2011)
6th annual pharmacovigilance conference (2011)6th annual pharmacovigilance conference (2011)
6th annual pharmacovigilance conference (2011)
 
Blurb 4th pv 2013
Blurb 4th pv 2013Blurb 4th pv 2013
Blurb 4th pv 2013
 
11th Annual Biosimilars Uk (2012)
11th Annual Biosimilars Uk (2012)11th Annual Biosimilars Uk (2012)
11th Annual Biosimilars Uk (2012)
 
9th pharmacovigilance 2015
9th pharmacovigilance 20159th pharmacovigilance 2015
9th pharmacovigilance 2015
 
Drug Regulatory Affairs
Drug Regulatory AffairsDrug Regulatory Affairs
Drug Regulatory Affairs
 
How is digital innovation affecting the pharmaceutical industry- Presentation
How is digital innovation affecting the pharmaceutical industry- PresentationHow is digital innovation affecting the pharmaceutical industry- Presentation
How is digital innovation affecting the pharmaceutical industry- Presentation
 
Redefining pharmacovigilance-with-social-media
Redefining pharmacovigilance-with-social-mediaRedefining pharmacovigilance-with-social-media
Redefining pharmacovigilance-with-social-media
 

Pharmacovigilance 2010

  • 1. Pharmacovigilance 2010 "Overseeing risks & Optimizing drug safety in today’s pharma market” January 21st - 22nd 2010, (Venue TBC), Mumbai, India Key Speakers: Veena Rajan, Head - Patient Safety, AstraZeneca Viraj Rajadhyaksha, Senior Manager, Operations, Planning & Management Clinical Research, Pfizer Simrat Sohal, Head - Pharmacovigilance, Eli Lilly Bhaswat S. Chakraborty, Senior VP, R&D, Cadila Pharmaceuticals Prashanth BSB, Medical & Safety expert (Regulatory Affairs), Cipla Deven Parmar MD, Vice President - Clinical Research & Pharmacovigilance, Wockhardt Milind Antani, Head-Pharma LifeSciences group, Nishith Desai Associates Arani Chatterjee, Vice President, Clinical Research, Panacea Biotec Arunima Sen, Manager Medical Team, MMS Holdings Incorporation Krathish Bopanna, Senior Vice President, Acunova D.D.Gupta, Vice President, Indian Pharmacological Society Gopal Pande, Scientist, Center for Cellular & Molecular Biology Media Partners Organised By
  • 2. Pharmacovigilance 2010 January 21st, 22nd 2010, Hotel (TBC), Mumbai, India. Conference Intro: Pharmacovigilance is the science and actions relating to discovery, evaluation, understanding and prevention of adverse effects or any other likely medicine related problems. The main aim of pharmacovigilance is to improve patient care and safety in relation to the use of medicines and other interventions. Despite all the benefits of medicines in disease management, there continues to be problems related to adverse reactions which are important cause for morbidity and morality in many countries. Significant harm to even a few patients not only destroys the credibility of the medicine, the patients also tend to loose trust on health system. A good Pharmacovigilance system will identify the risks in the shortest possible time, so that any harm can be avoided or minimized. The most frightening thought for any pharma company is the prospect of a drug withdrawal. As the costs associated with product withdrawals escalate, the importance of pharmacovigilance increases. Pharmacovigilance 2010 conference will discuss the on-going pressing concerns faced in drug safety, addressing the risks, timeline and budget constraints, whilst effectively tackling key challenges in overcoming trials agreement and site contract negotiation hurdles. This conference brings together top pharmaceutical, biotechnology and regulatory representatives in a forum that addresses the key issues of the industry. The in-depth program covers discussion on the detection, analysis and prevention of adverse drug reactions with case studies and industry experiences. Understand and learn the latest insights, tools and knowledge to ensure that you and your firm catch up with the current and future market. Analyze along with the market leaders, the latest developments in pharmacovigiance which would shape your organization-wide risk management strategy. Reasons to Register: Reviewing the best revenue generating models suitable for current and future PV market. · Who Should Attend: Grabbing the opportunity: learning about the challenges & complexities in the role · · practices, service offerings & deployment Best VP's, Directors, CRO's, Heads and Managers of: Global marketing strategies in order to engage with regulatory centres of excellence on · pharmacovigilance and to understand their perspectives on best practice & future trends Pharmacovigilance Strategy ? Improving patient care and safety in relation to use of medicines and all · ?Safety/Risk Management Drug medical and paramedical interventions Information and Clinical Data Management ? Exploiting the role of electronic data standards and controlled vocabularies in pharmacovigilance · ? Research & Development Clinical Positioning yourself in light of new market entries · Product Safety/Assurance Assessment ? Analyzing the worldwide trends in PV & lessons for India. · ? Safety, Outcomes Research & Data Analysis Patient Discover approaches for collecting, integrating and analyzing all of the safety data generated · Epidemiology project management ? from preclinical models Regulatory Affairs and Compliance ? Updating yourself with legislations, policies, systems, technology, · ? & Marketing Sales communication strategies and best practice in PV ? manufacturers Biotech Dwell ahead of regulatory developments & improving your risk management strategies in a cost · effective way Target Audience: Why should you attend: Pharmaceutical and Biotechnological Companies ? Contract Research Organisations (CROs), ? Pharmacovigilance 2010 - "Overseeing risks & Optimizing drug safety in Contract Manufacturing Organisations (CMOs), ? today's pharma market” ?Regulators, Drug Get more from the event, with a broader scope bringing the whole Intellectual Property/Law Firms, ? communications value chain together. Enjoy and make the best out of Academia, ? our dedicated networking drinks time, meet the leading international Government Bodies, Regulatory Affairs, Clinical Research Scientists ? vendors showcasing the products of tomorrow in the co-located Pharmaceutical manufacturing and distributing companies ? exhibition. Expand your knowledge of the latest business models and Wholesalers ? strategies in the high-level conference. Pharmaceutical packaging and labelling companies ? ? suppliers Service Pharmaceutical specialist couriers ? ? health and regulatory bodies, Public Anti-counterfeiting organisations ? Non-governmental healthcare organisations ? Delegate Registration: ? Recruitment Companies Patient Non-profit Organisations/Association, Consultants ? To register and to book your seats at the conference - please email your interest to delegate@virtueinsight.com Sponsorship & Exhibition Opportunities: If you would like to benefit by promoting your organization at one of About Virtue Insight: our events then exhibit is perfect for you. Virtue Insight equips business professionals around the world with the latest indepth · Hosting a networking drinks reception industry knowledge and provides networking opportunities in the telecom and · Increase and maintain brand awareness pharmaceutical industry. Our aim is to provide a platform to share knowledge and · Taking an exhibition space at the conference insights and provide our event attendees to network effectively and deliver maximum · Target your marketing campaign ROI by make new business alliances. We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the · Advertising in the delegate documentation pack industry. · Providing branded bags, pens, gifts, etc. · Network with industry decision-makers Our motto is to offer our customers the expertise and connections for a profitable · Meet potential clients & Present your products and ideas business. Our events encompass an optimum chance to gain maximum value in terms of networking and an opportunity to sponsor and exhibit to attract new business Any questions on Sponsorships or Exhibition – Email your queries to alliances. sarika.sareen@virtueinsight.com
  • 3. Pharmacovigilance 2010 Day One, 21st January 2010 08:45 - Coffee and registration - An opportunity to meet and to network with your conference colleagues. 14:40 – Growth of pharmacovigilance systems - India 09:30 - Chair's opening remarks ? of developing PV in India Benefits Arani Chatterjee, Vice President, Clinical Research Panacea Biotec ? Analyzing the current and the future of PV in India 09:40 - Observe the current & future market of Pharmacovigilance Demand for efficient PV by middle class Indians ? Analysing the current market situation and revealing the key revenue ? Deven Parmar MD, Vice President - Clinical Research & drivers for the future markets. Pharmacovigilance, Wockhardt ? are the steps to be taken if the industry is to achieve full What 15:20 – Afternoon tea potential? Challenges and Opportunities in 21st Century Safety Testing ? 15:40 – Panel Discussion - Regulator's perspective Determine the key considerations in implementing a progressive ? ? Pharmacovigilance from the Regulator's Perspective – Latest Updates pharmacovigilance strategy ? Understanding how companies can work more successfully with regulators 10:20 - Next generation pharmacovigilance - opportunities and finding solutions to the challenges of drug safety ? What can the regulators do to help industry? ? Highlighting the critical new importance of pharmacovigilance and risk ? Determining the best strategy to secure approval. management for successful drug development ? An overview of the Global Regulatory Safety Information Database ? New opportunities for high performance in pharmacovigilance ? Elaborating the new globalization of pharmacovigilance standards Moderator: 11:00 – Morning coffee & Discussion Milind Antani, Head-Pharma LifeSciences group, Nishith Desai Associates 11:20 – Pre-Approval periodic safety reporting using DSUR & post marketing reporting using PSUR - Understanding the essentials Panellists: Sanish Davis, Clinical research manager, PGRD, Pfizer 16:20 – Emerging technologies and strategies for drug safety evaluation 12:00– Panel discussion: Challenges in upcoming markets ? key technologies for predicting drug safety in the earliest stages of Assess ? Successful strategies to face the future challenges in pharmacovigilance discovery and clinical development ? Analyzing the changing business environment ? Analyzing the role of public-private consortia in solving key issues within the field of predictive safety. ? Evaluating where are the opportunities and threats in emerging markets ? predictive safety technologies can provide potential cost savings Which and improvements in attrition rates and assess the challenges and risks Moderator: associated with the implementation. Gopal Pande, Scientist, Center for Cellular & Molecular Biology ? Understand the latest strategies to improve safety evaluation in early clinical development Panellists: Arunima Sen, Manager Medical Team, MMS Holdings Incorporation 17:00 – Chairperson's closing remarks and End of Conference Veena Rajan, Head - Patient Safety, AstraZeneca 12:40 – Networking luncheon 14:00 - Role of Therapeutic alliance in PV 17:20 - Networking Drinks - Take your discussions further & build new relationships in a relaxed D.D.Gupta, Vice President, Indian Pharmacological Society & informal setting...
  • 4. Pharmacovigilance 2010 Day Two, 22nd January 2010 08:45 – Coffee and registration – An opportunity to meet and to 14:00 – Pharmacovigilance quality assurance network with your conference colleagues. ·Pharmacovigilance QA as a Corporate competitive advantage 09:30 – Chair's opening remarks ·Pharmacovigilance QA Surveillace Programme TBC ·Application of Quality Risk Management principles for ensuring an effective PV audit programme 09:40 – Data mining & signal detection in Pharmacovigilance ·Creation of PV Quality Indicators for monitoring status of quality and future auditing needs Bhaswat S. Chakraborty, Senio VP, R&D, Cadila Pharmaceuticals ·Electronic-submissions and the associated quality issues 10:20 – Pharmacovigilance in focus ·Economic impact of ADR 14:40 – Risk management - ·Thalidomide status through PV ·Lessons to be learned from extensive drug safety research ·Real lessons from Vioxx ·Cutting-edge risk management, how to prepare for the wWorst ·Best-selling drugs & adv through PV for these drugs ·Managing developments and adapting to changing ·Practical problems & Challenges in PV information ·Penalties on non-complaiance to PV ·Constant improvement in risk management strategies Prashanth BSB, Medical & Safety expert (Regulatory Affairs), Cipla ·Developing and maintaining exemplary drug safety standards 11:00 – Morning coffee & Discussion 15:20 – Afternoon tea 11:20 – Panel Discussion - Working towards patient subject safety from early development 15:40 – Challenges in Pharmacovigilance: Different Sponsors, Same Drug ·Advanced Pharmacology Techniques and Methodologies to Improve Safety ?are current “best practices” in this challenging area? What ·Putting the patient first – The importance of developing a ? “continuous safety monitoring” be achieved? How can comprehensive post-marketing surveillance strategy ·What are issues in signal detection across sponsors and trans-nationally? Moderator: ·Best methods for pharmacovigilance, signal detection, risk management in this setting Panellists: Atul Jain, Vice-principal & Professor & Head of Pharmacology 16:20 – Panel Discussion – SWOT analysis Deptt., T.M.U.Medical College Strength, Weakness, Opportunities & Threats of Pharmacovigilance in India 12:00 – Challenges in the local regulations for pharmcovigilnce (Overall review of this Pharmacovigilance 2010 conference) Simrat Sohal, Head - Pharmacovigilance, Eli Lilly Moderator: 12:40 – Networking luncheon Panellists: Krathish Bopanna, Senior Vice President, Acunova Viraj Rajadhyaksha, Senior Manager, Operations, Planning & Management Clinical Research, Pfizer, India 17:00 – Chairperson's closing remarks and End of Conference
  • 5. Registration Form Pharmacovigilance 2010 21st - 22nd January, 2010 For Multiple Bookings Photocopy this form... Queries: Special Price INR (Please Tick) Should you have any questions on bookings, Please feel free to contact us. 2 Day conference Fee: INR 12,000 + Tax 1 Day conference Fee: INR 7,000 + Tax Email: delegate@virtueinsight.com Web: http://www.virtueinsight.com Academic Price (Students) India Office: Tel: +0091 44 64998743 2 Day conference Fee: INR 5,000 + Tax 1 Day conference Fee: INR 3,000 + Tax Payment terms: Virtue Insight requires the full amount to be paid before the Registration Form Details: conference. Virtue Insight may refuse entry to delegates who have not paid their invoice in full. Forename ............................Surname ................................ Substitutions/name changes or cancellations: There is a 50% liability on all bookings once made, whether by post, Job Title ..............................Company ................................ fax, or email. There is a no refund policy for cancellations received on or after one month before the start of the event. Should you decide to cancel after this date, the full invoice must be paid. Conference Official Contact Number ....................................................... notes will then be sent to you. Unfortunately, we are unable to transfer places between conferences and executive briefings. However, if you cannot attend the conference, you may make a substitution/name Address ............................................................................. change at any time, as long as we are informed in writing by email, fax or post. Name changes and substitutions must be from the same company or organization and are not transferable between countries. ............................................................................. Indemnity: Virtue Insight reserves the right to make alterations to the Country ...............................Postcode.................................. conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of Virtue Insight. If such a Phone ..................................Fax ........................................ situation arises, we will refund your registration fee and we will try to reschedule the event. Email ................................................................................. Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel or hotel I confirm that I have read & agree to the accommodation. terms and conditions of booking..... (Please Tick) How we will contact you: Virtue Insight's preferred method of communication is by email and Signature ........................................................................... phone. Please ensure that you complete the registration form in full so that we can contact you. Methods of Payments: By Cheque - Complete and return the above registration form via post or email, together with your cheque payable to Virtue Insight. By Bank Transfer - Account Name - Virtue Insight News Updates: Account Number - 830092431 Bank Address - Indian Bank. Please tick if you do not wish to receive email updates in 118 - 119, Indira Nagar, Valasaravakkam, the future Chennai 600 087,Tiruvallur district,Tamil Nadu, India www.virtueinsight.com